1 Min Read
LONDON, Oct 23 (Reuters) - An experimental Amgen drug based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for the novel treatment's approval within a couple of months.
The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness.
The European Medicines Agency said its experts had recommended approval of talimogene laherparepvec or "T-Vec" for treating melanoma, making it another option among several new drugs for fighting for the most deadly form of skin cancer. (Reporting by Ben Hirschler; editing by Jason Neely)